Abstract | PURPOSE: METHODS AND RESULTS: CONCLUSION:
Rituximab may be a treatment alternative in severe scleritis that is refractive to conventional therapy. Considering its safety profile, further studies are needed to refine its mechanism of action, optimal indications, and dosing in ocular inflammation.
|
Authors | Barbara Iaccheri, Sofia Androudi, Elena Bartoloni Bocci, Roberto Gerli, Carlo Cagini, Tito Fiore |
Journal | Ocular immunology and inflammation
(Ocul Immunol Inflamm)
Vol. 18
Issue 3
Pg. 223-5
(Jun 2010)
ISSN: 1744-5078 [Electronic] England |
PMID | 20482403
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Antirheumatic Agents
- Rituximab
|
Topics |
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage, therapeutic use)
- Antirheumatic Agents
(administration & dosage, therapeutic use)
- Arthritis, Rheumatoid
(complications)
- Dose-Response Relationship, Drug
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Remission Induction
- Rituximab
- Scleritis
(drug therapy, etiology)
|